Apolipoprotein E Genotyping and Cerebrospinal Fluid Tau Protein: Implications for the Clinical Diagnosis of Alzheimer’s Disease

Gerontology

Volumn 43, Issue , 1997, Pages 2-10

  Arai, Hiroyuki ^a   Higuchi, Susumu ^b   Sasaki, Hidetada ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURIHAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Alzheimer s disease; Apolipoprotein E gene; Biological marker; Cerebrospinal fluid; Presenilin 1 gene; Tau protein; 1 Antichymotrypsin gene

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; APOLIPOPROTEIN E; CYANOCOBALAMIN; TAU PROTEIN;

ADULT; AGED; ALCOHOLISM; ALZHEIMER DISEASE; BRAIN DISEASE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; CYANOCOBALAMIN DEFICIENCY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENINGOENCEPHALITIS; MULTIINFARCT DEMENTIA; NEUROLOGIC DISEASE; NORMOTENSIVE HYDROCEPHALUS; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; GENOTYPE; HUMANS; TAU PROTEINS;

EID: 0030989926     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000213879     Document Type: Article

References (35)

1. Arai H, Lee VM-Y, Otvos L Jr., Greenberg BD, Lowery DE, Sharma SK, Schmidt ML, Trojanowski JQ: Defined ncurofilament, T and B-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques, Proc Natl Acad Sci USA 1990;87:2249-2253.
2. Trojanowski JQ, Clark CM, Schmidt ML, Arai H, Zhu C, Ma-wal-Dcwan M, Lee VM-Y: Implications of tau-rich neurofibrillary lesions for the pathobiology and diagnosis of Alzheimer’s disease; in Appel S (ed): Current Neurology, vol 16. St Louis, Mosby Year Book, 1996. pp 93-113.
3. American Psychiatric Association: Diagnostic and Statistical Manuals of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
4. McKhaan G, Drachman D, Folstcin M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology 1984;34:939-944.
5. Kachaturian ZS: Diagnosis of Alzheimer's disease, Arch Neurol 1985: 42:1097-1105.
6. Motter R, Vigo-Pelfrey C, Kholo-denko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Licbcrburg I, Seubert P, Schenk D: Reduction of p-amyloid peptidcj; in the cerebrospinal fluid of patients with Alzheimer's disease, Ann Neurol 1995;38:643-648.
7. Van Nostrand WE, Wagner SL, Shanklc WR, Farrow JS, Dick M, Rosemuller JM, Kuipcr MA, Wol-ters EC, Zimmerman J, Cotman CW, Cunningham DD: Decreased levels of soluble amyloid p protein precursor in cerebrospinal fluid of live Alzheimer’s disease patients, Proc Natl Acad Sci USA 1992:89: 2551-2555.
8. Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, Co-ria F, Chang L, Miller B, Licbcrburg I, Schenk D: Elevation of microtu-bulc-associatcd protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease, Neurology 1995;45:788-793.
9. Joachim C, Mori H, Selkoe D: Amyloid beta-protein deposition in tissues other than brain in Alzheimer’s disease, Nature 1989:341:226-230.
10. Arai H, Lee VM-Y, Mcssinger ML, Greenberg BD, Lowery DE, Trojanowski JQ: Expression patternsofp-amyloid precursor protein (P-APP) in neural and nonncural human tissues from Alzheimer’s disease and control subjects, Ann Neurol 1991; 30:686-693.
11. Scinto LFM, Daffner KR, Dressner D, Ransil BI, Rentz D, Weintraub S, Mesulam M, Potter H: A potential noninvasive ncurobiological test for Alzheimer’s disease, Science 1994: 266:1051-1053.
12. Arai H, Terajima T, Nakagawa T, Higuchi S, Mochizuki H, Sasaki H: Pupil dilatation assay by tropicam-ide is modulated by apolipoprotein E 84 allele dosage in Alzheimer’s disease, Neuroreport 1996:7:918-920.
13. Strittmattcr WJ, Saunder AM, Schmechel D, Pericak-Vancc M, Enghild J, Salvcscn GS, Roses AD: ApoE: High avidity binding to p-amvloid and increased frequency of type 4 allele in late onset familial Alzheimer disease, Proc Natl Acad Sci USA 1993;90:1977-1981.
14. Cordcr EH, Saunders AM, Strittmattcr WJ, Schmechel DC, Gaskell PC, Small WG, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type4 allele and the risk of Alzheimer’s disease in late onset families, Science 1993: 261:921-923.
15. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikcda K: Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutz-feld-Jacob disease, Brain Res 1991; 541:163-166.
16. Bao F, Arai H, Matsushita S, Higuchi S, Sasaki S: Expression of apolipoprotein E in normal and diverse neurodcgcnerativc disease brain, Neurorcport 1996;7:1733-1739.
17. Arai H, Muramatsu T, Higuchi S, Sasaki H, Trojanowski JQ: Apolipoprotein E gene in Parkinson’s disease with or without dementia, Lancet 1994:344:889.
18. Arai H, Schmidt ML, Lee VM-Y, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ: Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson’s disease, Neurology 1992;42:1315-1322.
19. Arai H, Higuchi S, Muramatsu T, Iwatsubo T, Sasaki H, Trojanowski JQ: Apolipoprotein E gene in diffuse Lew-y body disease with or without co-existing Alzheimer’s disease, Lancet 1994:244:1307.
20. Muramatsu T, Higuchi S, Arai H, Sasaki H, Yamada K, Hayashida M, Trojanowski JQ: Apolipoprotein E e4 allele distribution in alcoholic dementia and in Alzheimer’s disease in Japan, Ann Neurol 1994;36:797-799.
21. Higuchi S, Arai H, Nakagawa T, Muramatsu T, Sasaki H, Trojanowski JQ: The apolipoprotein E gene in Binswanger’s disease and vascular dementia, Clin Genet 1996. in press.
22. Arai H, Higuchi S, Muramatsu T, Matsushita S, Itabashi S, Sasaki H: Lack of association of apolipoprotein E E4 allele with progressive supranuclear palsy, Neurodegeneration 1996:5:194-195.
23. Yamaguchi S, Nakagawa S, Arai H, Sasaki H, Higuchi S, Trojanowski JQ: Temporal progression of hippocampal atrophy and apolipoprotein E gene in Alzheimer’s disease, J Am GeriatrSoc 1996;44:216-217.
24. National Institute on Aging/ Alzheimer's Association Working Group: Apolipoprotein E genotyp-ing in Alzheimer’s disease, Lancet 1996:347:1091-1095.
25. Higuchi S, Matsushita S, Hasegawa Y, Muramatsu T, Itabashi S, Arai H: SI82 and STM2 missense mutations in sporadic Alzheimer’s disease, Am J Med Genet 1996:67:429.
26. Kamboh MI, Sanghcra DK, Ferrell RE, DcKosky ST: Apo E4-associat-cd Alzheimer's disease risk is modified by al-antichymotrypsin polymorphism, Nature Genet 1995:10: 486-488.
27. Muramatsu T, Matsushita S, Arai H, Sasaki H, Higuchi S: di-Antichy-motrypsin gene polymorphism and risk for Alzheimer’s disease, J Neural Transm 1996; 103:1205-1210.
28. Wragg M, Hutten M, Talboot C, Alzheimer's Disease Collaborative Group: Genetic association between intronic polymorphism in presenil-in-1 gene and late-onset Alzheimer’s disease, Lancet 1996:347:509-512.
29. Higuchi S, Muramatsu T, Matsushita S, Arai H, Sasaki H: Presenilin-1 polymorphism and Alzheimer's disease, Lancet 1996:347:1185-1187.
30. Lee VM-Y, Balin BJ, Otvos L Jr., Trojanowski JQ: A68: A major subunit of paired filaments and dcriva-lized forms of normal tau, Science 1991;251:675-678.
31. Vandermeeren M, Mercken M, Vanmechclen E, Six J, Van de Voordc A, Martin J-J, Cras P: Detection of r proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay, J Neurochem 1993:61:1828-1834.
32. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, Seki H, Takase S, Clark CM, Lee VM-Y, Trojanowski JQ, Sasaki H: Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer’s disease, Ann Neurol 1995:38: 649-652.
33. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Matsushita S, Machida N, Nakagawa T, Lee VM-Y, Trojanowski JQ, Sasaki H: Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer’s disease, J Am Geriatr Soc 1997. in press.
34. Terajima M, Arai H, Itabashi S, Higuchi M, Zhu C, Sasaki H: Elevated cerebrospinal fluid tau levels: Implications for the early diagnosis of Alzheimer's disease, J Am Geriatr Soc 1996:44:1012-1013.
35. Trojanowski JQ, Clark CM, Arai H, Lee VM-Y: Elevated levels of tau in cerebrospinal fluid: Implications for the antemortcm diagnosis of Alzheimer’s disease, Alzheimer Dis Rev 1996;1:77-83.